Connect
MJA
MJA

Individualising type 2 diabetes management: new treatment options and models of care

N Wah Cheung
Med J Aust 2012; 197 (4): . || doi: 10.5694/mja12.11041
Published online: 20 August 2012

Better outcomes require tailored strategies

The past 15 years has seen the advent of many new classes of antidiabetic agents. We now have biguanides, sulfonylureas, thiazolidinediones, dipeptidyl-peptidase IV inhibitors, glucagon-like peptide 1 receptor agonists, a variety of insulins and α-glucosidase inhibitors. This has resulted in a surfeit of choice, but has also increased the complexity of decision making as there is no simple algorithm for escalation of treatment that is optimal for all patients.


  • Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, NSW.


Correspondence: wah.cheung@sydney.edu.au

Competing interests:

I am the President of the Australian Diabetes Society and a member of the Australian Government’s Diabetes Advisory Group for the Diabetes Care Project.

  • 1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care 2012; 35: 1364-1379.
  • 2. Cheung NW, Conn JJ, D’Emden MC, et al. Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus. Med J Aust 2009; 191: 339-344. <MJA full text>
  • 3. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
  • 4. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
  • 5. NHS Employers. Quality and outcomes framework for 2012/13: guidance for PCOs and practices. London: NHS Employers, 2012.
  • 6. Hayward RA, Krumholz HM, Zulman DM, et al. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Int Med 2010; 152: 69-77.
  • 7. Dalton ARH, Alshamsan R, Majeed A, Millett C. Exclusion of patients from quality measurement of diabetes care in the UK pay-for-performance programme. Diabet Med 2011; 28: 525-531.
  • 8. Diabetes Care Project [website]. https://www.dcp.org.au/public/index.cfm (accessed Jun 2012).
  • 9. O’Connor PJ, Bodkin NL, Fradkin J, et al. Diabetes performance measures: current stats and future directions. Diabetes Care 2011; 34: 1651-1658.
  • 10. Moore DE. How doctors think: clinical judgment and the practice of medicine, by Kathryn Montgomery [book review]. JAMA 2006; 295: 2080-2081.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.